Nature14y
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins. In addition, there is inhibition of expression of ...
Bio-Path Holdings Reports Full Year 2024 Financial Results
General and administrative expense for the year ended December 31, 2024 increased to $4.7 million, compared to $4.2 million for the year ended December 31, 2023 primarily due to increased salaries and ...
Hosted on MSN1mon
Bio-Path Holdings expands global patent portfolio
The U.S. Patent and Trademark Office granted a Notice of Allowance for a patent titled "P-ethoxy nucleic acids for STAT3 inhibition," and the New Zealand Intellectual Property Office awarded ...
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Updated results from BP1001-A obesity and Type 2 diabetes testing from the second stage of pre-clinical testing are as follows: Previously, Bio-Path reported BP1001-A increased insulin sensitivity in ...